Ovid Therapeutics (OVID) Price to FCF (2017 - 2026)

Ovid Therapeutics (OVID) has reported Price to FCF for 10 consecutive years, with 28.24 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to FCF fell 474.48% year-over-year to 28.24; the trailing twelve-month figure through Jun 2026 stood at 9.07 (down 1448.15% YoY), and the FY2025 full-year result was 3.14, down 166.09% from the prior year.
• Price to FCF retreated to 28.24 in Q2 2026 per OVID's latest filing, from 21.75 in the prior quarter.
• Across five years, Price to FCF topped out at 2.14 in Q1 2025 and bottomed at 28.24 in Q2 2026.
• Historically, Price to FCF has averaged 12.85 across 5 years, with a median of 11.27 in 2022.
• The sharpest annual moves came in 2025 and 2026: Price to FCF surged 83.41% in 2025, then plunged 914.21% in 2026.
• Over 5 years, Price to FCF stood at 14.1 in 2022, then plunged by 35.69% to 19.13 in 2023, then jumped by 65.42% to 6.62 in 2024, then slumped by 74.55% to 11.55 in 2025, then sank by 144.53% to 28.24 in 2026.
• According to Business Quant data, Price to FCF over the past three periods registered 28.24, 21.75, and 11.55 for Q2 2026, Q1 2026, and Q4 2025 respectively.